18:02 EDT Procept BioRobotics (PRCT) sees Q2 revenue $79.2M, consensus $75.94M
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics completes WATER IV trial procedures
- Leerink sees positive readthrough for Procept after CMS’ OPPS proposed rule
- 3 Best Stocks to Buy Now, 7/16/2025, According to Top Analysts
- Procept BioRobotics price target lowered to $68 from $71 at Morgan Stanley
- Positive Outlook on PROCEPT BioRobotics Amid New Fee Schedule Developments for Aquablation